Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
26 4월 2022 - 9:45PM
Business Wire
Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL)
announced today that Evaxion will deploy Personalis’ ImmunoID NeXT
Platform in a Phase 2b trial to evaluate the efficacy and safety of
Evaxion’s personalized cancer immunotherapy EVX-01. The study will
combine EVX-01, a neoepitope-targeting immunotherapy based on
Evaxion’s proprietary PIONEER® AI technology, with KEYTRUDA®
(pembrolizumab) for the treatment of patients with metastatic
melanoma.
“We believe we have found the key to efficiently activating the
immune system to combat cancer. With our core AI tool called
PIONEER, we accurately predict the patient’s most potent
neoepitopes, which are the significant mutations of cancer. Then we
train the immune system to target those exact mutations, not
everything else. That means a higher precision in the therapy than
the standard of care treatments out there,” said Lars Wegner, CEO
of Evaxion. “We are happy to work with Personalis on this crucial
next step when we embark on the Phase 2b study, potentially
bringing us closer to fulfilling our aspiration of saving the lives
of patients with our AI-powered immunotherapy.”
“Over the past decade, a number of drugs have emerged based on
the discovery that the immune system plays a key role in fighting
cancer. However, the development of new therapies has been
challenged by difficulties in understanding the precise interaction
between cancer and the immune system,” said John West, CEO and
co-founder of Personalis. “ImmunoID NeXT provides a broad set of
insights on tumor and immune biology. Our collaboration with
Evaxion may contribute to a better understanding of how combination
therapeutics can improve patient outcomes and offer the path to
companion diagnostics when relevant biomarkers are identified.”
ImmunoID NeXT® provides a comprehensive, multidimensional view
of both a tumor and its immune microenvironment from a single
sample. The platform consolidates multiple biomarker assays into
one, including advanced analysis of mechanisms of tumor escape,
human leukocyte antigen typing and loss of heterozygosity,
microsatellite instability, gene expression signatures, T-cell and
B-cell receptor repertoires, and immunocellular quantification.
ImmunoID NeXT offers a seamless platform for discovery, from
translational testing to companion diagnostics.
About Evaxion
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform
company decoding the human immune system to discover and develop
novel immunotherapies to treat cancer, bacterial diseases and viral
infections. Based on its proprietary and scalable AI-immunology
core technology, Evaxion is developing a broad pipeline of novel
product candidates, which currently includes three patient-specific
cancer immunotherapies.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics,
enabling the next generation of precision cancer therapies and
diagnostics. The Personalis NeXT Platform® is designed to adapt to
the complex and evolving understanding of cancer, providing its
biopharmaceutical customers and clinicians with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single sample. To enable cancer sequencing,
Personalis' Clinical Laboratory was built with a focus on clinical
accuracy, quality, big data, scale, and efficiency. The laboratory
is GxP-aligned as well as Clinical Laboratory Improvement
Amendments of 1988-certified and College of American
Pathologists-accredited. For more information, visit the Personalis
website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the Personalis NeXT Platform, expected benefits of Personalis’
collaboration with Evaxion, Personalis’ business opportunities,
leadership, plans or expectations, or other future events. Such
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements. Factors that could materially affect actual results can
be found in Personalis’ filings with the U.S. Securities and
Exchange Commission, including Personalis’ most recent reports on
Forms 8-K, 10-K and 10-Q, the company’s registration statement on
Form S-3 filed on December 30, 2020, and the company’s prospectus
supplement filed on January 3, 2022, and include those listed under
the caption “Risk Factors.” Personalis disclaims any obligation to
update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220426005194/en/
Media Contact for Evaxion: Katrine Hertz Mortensen
khm@evaxion-biotech.com www.evaxion-biotech.com +45 3010 0203
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Temple
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024